Skip to main content
Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
152.43
-2.15 (-1.39%)
Feb 21, 2025, 4:00 PM EST - Market closed

Ascendis Pharma External Customers Revenue
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Research and Development
225.73M 217.85M 209.11M 213.61M 178.66M 131.50M 96.78M 65.32M
Research and Development Growth
26.34% 65.67% 116.06% 227.01% 401.03% - - -
License
122.34M 90.79M 90.51M 90.23M 66.08M 2.41M 2.48M 2.53M
License Growth
85.15% 3,668.91% 3,557.09% 3,467.93% 2,494.31% - - -
Milestone
15.57M 18.79M 18.01M 25.18M 21.98M 18.01M 19.91M 10.08M
Milestone Growth
-29.16% 4.34% -9.55% 149.69% 69.48% - - -

Operating Metrics

Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Total Skytrofa Revenue
209.70M 209.49M 219.54M 185.35M 136.66M 100.70M 68.07M 36.88M
Total Skytrofa Revenue Growth
53.45% 108.02% 222.53% 402.53% - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.